Immunotherapy

GPhC writes to pharmacy teams after methotrexate dispensed with instruction to take once daily

An email sent by Roz Gittins, chief pharmacy officer at the GPhC, advised pharmacy teams to supply methotrexate in line with a drug safety update published by the MHRA in September 2020.…

Bruton tyrosine kinase inhibitors and B-cell malignancies: a guide for pharmacists

This learning article with interactive elements provides an overview of the available Bruton tyrosine kinase inhibitors for the treatment of B-cell malignancies to support pharmacists with their use in practice.…

Supported content

NICE recommends first immunotherapy for limited-stage small cell lung cancer

Guidance says that durvalumab can be used alongside active monitoring of patients who have completed chemotherapy.…

MHRA approves UK’s first immunotherapy for type 1 diabetes

Teplizumab (Tzield; Sanofi) has been approved by the MHRA for delaying the progression of type 1 diabetes mellitus.…

Case-based learning: complex decision making when using advanced therapy investigational medicinal products

Advanced therapy investigational medicinal products (ATIMPs) are increasingly the subject of clinical trials. What happens when an ATIMP is necessary for a patient but does not fit the study specifications?…

SARS-CoV2 antivirals are essential, but they are not silver bullets

The UK government's 'living with COVID-19' policy is relying too much on antiviral treatments, but now is not the time to relax.…

Collaborate to deliver biggest ever flu vaccination programme, RPS and RCGP say

Pharmacists and GPs should work together to make sure as many people as possible get their flu vaccination this winter, the Royal Pharmaceutical Society and the Royal College of General Practitioners have said.…

Going against type: the new class of cancer therapies targeting mutations rather than tissues

‘Tumour agnostic’ drugs offer a more effective and tolerable therapy for a wide range of people with cancer, so why has the NHS rejected its first one?…

Combination immunotherapy for melanoma improves long-term survival rates

Patients with advanced melanoma treated with a combination of ipilimumab and nivolumab are more likely to be alive five years later than patients treated with ipilimumab alone or nivolumab alone.…